SG11201407875UA - Compostions and methods for cancer immunotherapy - Google Patents
Compostions and methods for cancer immunotherapyInfo
- Publication number
- SG11201407875UA SG11201407875UA SG11201407875UA SG11201407875UA SG11201407875UA SG 11201407875U A SG11201407875U A SG 11201407875UA SG 11201407875U A SG11201407875U A SG 11201407875UA SG 11201407875U A SG11201407875U A SG 11201407875UA SG 11201407875U A SG11201407875U A SG 11201407875UA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- llll
- iii
- suite
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 abstract 2
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 108091007930 cytoplasmic receptors Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657574P | 2012-06-08 | 2012-06-08 | |
PCT/US2013/044744 WO2013185052A1 (en) | 2012-06-08 | 2013-06-07 | Compostions and methods for cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407875UA true SG11201407875UA (en) | 2014-12-30 |
Family
ID=49712686
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201610251PA SG10201610251PA (en) | 2012-06-08 | 2013-06-07 | Compositions and methods for cancer immunotherapy |
SG11201407875UA SG11201407875UA (en) | 2012-06-08 | 2013-06-07 | Compostions and methods for cancer immunotherapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201610251PA SG10201610251PA (en) | 2012-06-08 | 2013-06-07 | Compositions and methods for cancer immunotherapy |
Country Status (12)
Country | Link |
---|---|
US (1) | US9770467B2 (zh) |
EP (1) | EP2858722B8 (zh) |
JP (1) | JP6257607B2 (zh) |
KR (1) | KR20150022996A (zh) |
CN (1) | CN104507538B (zh) |
AU (1) | AU2013271375B2 (zh) |
CA (1) | CA2876150A1 (zh) |
HK (1) | HK1204302A1 (zh) |
IN (1) | IN2014MN02492A (zh) |
NZ (1) | NZ702392A (zh) |
SG (2) | SG10201610251PA (zh) |
WO (1) | WO2013185052A1 (zh) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014MN02492A (zh) | 2012-06-08 | 2015-07-17 | Aduro Biotech | |
EP2931738B1 (en) | 2012-12-13 | 2019-02-06 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
AU2013363087B2 (en) | 2012-12-19 | 2018-07-19 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
SG11201508165VA (en) | 2013-04-29 | 2015-11-27 | Sloan Kettering Inst Cancer | Compositions and methods for altering second messenger signaling |
WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
CN105188373B (zh) * | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
BR112015030989A2 (pt) * | 2013-06-14 | 2019-09-24 | Intervet Int Bv | composição farmacêutica, e, uso de uma composição |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
US10421971B2 (en) * | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
US10450341B2 (en) | 2014-06-04 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of STING |
CA2958771A1 (en) * | 2014-09-08 | 2016-03-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
US10010607B2 (en) | 2014-09-16 | 2018-07-03 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response |
US11236139B2 (en) * | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
US11058758B2 (en) | 2014-11-20 | 2021-07-13 | National Institutes Of Biomedical Innovation, Health And Nutrition | TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same |
US20170340658A1 (en) * | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
EP3233882B1 (en) | 2014-12-16 | 2019-10-30 | Kayla Therapeutics | Fluorinated cyclic dinucleotides for cytokine induction |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
US10130663B2 (en) | 2015-02-11 | 2018-11-20 | The John Hopkins University | Bacteria over-expressing c-di-AMP and therapeutic methods |
WO2016179475A1 (en) * | 2015-05-07 | 2016-11-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
EP3334745B1 (en) | 2015-08-13 | 2024-05-15 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
CN106540255A (zh) * | 2015-09-18 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用 |
CN106540254A (zh) * | 2015-09-22 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP及其衍生物是潜在免疫佐剂 |
CN106540253A (zh) * | 2015-09-24 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | cGAMP及其衍生物在制备抗肿瘤疫苗中的应用 |
CN105367617A (zh) * | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用 |
CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
KR20180097751A (ko) | 2016-01-11 | 2018-08-31 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
CN106544319A (zh) * | 2016-01-24 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法 |
CN108779473A (zh) | 2016-03-16 | 2018-11-09 | 法国居里学院 | 用于制备具有环二核苷酸的病毒颗粒的方法和所述颗粒用于治疗癌症的用途 |
KR102530488B1 (ko) * | 2016-03-18 | 2023-05-08 | 이뮨 센서, 엘엘씨 | 사이클릭 디-뉴클레오티드 화합물 및 사용 방법 |
KR20180132783A (ko) | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조절제로서 유용한 헤테로사이클릭 아미드 |
KR102527784B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
MX2019000216A (es) | 2016-07-06 | 2019-11-12 | Sperovie Biosciences Inc | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
EP3922279A1 (en) | 2016-08-30 | 2021-12-15 | Dana Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
EA037513B1 (ru) * | 2016-09-17 | 2021-04-06 | ИММЬЮН СЕНСОР, ЭлЭлСи | Циклические динуклеотидные соединения и способы их применения |
CR20190168A (es) | 2016-10-04 | 2019-05-17 | Merck Sharp & Dohme | Compuestos de benzo[b]tiofeno como agonistas de sting |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
KR101889181B1 (ko) * | 2016-12-19 | 2018-08-16 | 주식회사 포스코 | 굽힘성 및 신장플랜지성이 우수한 고장력강 및 이의 제조방법 |
KR20190126761A (ko) * | 2016-12-22 | 2019-11-12 | 마브파마, 인크. | I형 ifn 생산을 증강 또는 증대하는 조성물 및 방법 |
US20190351039A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
US10933078B2 (en) | 2017-02-21 | 2021-03-02 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
EP3638252A4 (en) * | 2017-06-12 | 2021-03-10 | University of Miami | STING-DEPENDENT ACTIVATORS FOR THE TREATMENT OF A DISEASE |
US11969499B2 (en) | 2017-06-16 | 2024-04-30 | William Marsh Rice University | Hydrogel delivery of sting immunotherapy for treatment cancer |
US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
BR112020006780A2 (pt) | 2017-10-05 | 2020-10-06 | Glaxosmithkline Intellectual Property Development Limited | moduladores do estimulador de genes do interferon (sting) |
CN107619438B (zh) * | 2017-10-11 | 2021-12-03 | 广州云启科技有限公司 | 新型环二核苷酸受体及其激动剂或抑制剂筛选的方法和试剂盒 |
CN109694397B (zh) * | 2017-10-23 | 2021-08-31 | 上海弘翊生物科技有限公司 | 环状二核苷酸化合物、其制备方法和应用 |
WO2019092660A1 (en) | 2017-11-10 | 2019-05-16 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
IL309265A (en) | 2018-03-23 | 2024-02-01 | Codiak Biosciences Inc | Extracellular vesicles containing agonist-STING |
BR112020020085A8 (pt) | 2018-04-03 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir produção de interferons de tipo i dependentes de sting e para tratar um distúrbio de proliferação celular |
US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
CA3099904A1 (en) | 2018-08-16 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
AU2019372440A1 (en) * | 2018-11-02 | 2021-05-27 | The Regents Of The University Of California | Methods to diagnose and treat cancer using non-human nucleic acids |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
EP3941937A2 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Extracellular vesicles for vaccine delivery |
TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
JP7485399B2 (ja) * | 2019-08-21 | 2024-05-16 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子の刺激因子stingの単環式アゴニスト |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
MX2022003570A (es) | 2019-09-25 | 2022-07-11 | Codiak Biosciences Inc | Composiciones de vesícula extracelular. |
EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
AU2020351729A1 (en) | 2019-09-25 | 2022-04-21 | Lonza Sales Ag | STING agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ, インコーポレイテッド | 治療のための細胞外小胞 |
US20230225972A1 (en) * | 2020-04-15 | 2023-07-20 | Statens Serum Institut | Liposomal composition for preventing or early treatment of pathogenic infection |
WO2021216572A1 (en) | 2020-04-20 | 2021-10-28 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
JP7072604B2 (ja) * | 2020-06-23 | 2022-05-20 | アンスティテュ・クリー | 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用 |
CN111956797B (zh) * | 2020-07-10 | 2022-05-13 | 清华大学 | 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用 |
CA3192470A1 (en) | 2020-09-23 | 2022-03-31 | Tim SOOS | Methods of producing extracellular vesicles |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
WO2022118043A1 (en) * | 2020-12-03 | 2022-06-09 | Enara Bio Limited | Novel protein-ligand complex |
EP4326321A1 (en) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions and methods for use in immunotherapy |
EP4326769A1 (en) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions and methods for use in immunotherapy |
WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
AU741602B2 (en) | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
EP1153931B1 (en) | 1999-02-15 | 2005-07-20 | Nippon Shinyaku Co., Ltd. | Shortened-chain polynucleotides and process for the preparation thereof |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
DE60027719T2 (de) | 1999-06-14 | 2007-04-26 | Cancer Research Technology Ltd. | Krebstherapie |
US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
US20020150588A1 (en) | 2000-09-21 | 2002-10-17 | Allison James P. | SPAS-1 cancer antigen |
US7279883B2 (en) | 2001-01-23 | 2007-10-09 | Lydia L. Sohn | Particle analyzer and methods for use thereof |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US8367716B2 (en) | 2003-07-28 | 2013-02-05 | Karaolis David K R | Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
AU2004281834A1 (en) | 2003-10-15 | 2005-04-28 | Cerus Corporation | Listeria-based EphA2 vaccines |
EP1677765A1 (en) | 2003-10-24 | 2006-07-12 | Alza Corporation | Preparation of lipid particles |
US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
EP1729781B1 (en) | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US20060286549A1 (en) | 2005-05-06 | 2006-12-21 | The Regents Of The University Of California | Microfluidic system for identifying or sizing individual particles passing through a channel |
US20070059683A1 (en) | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
ES2548240T3 (es) | 2005-12-01 | 2015-10-15 | Pronai Therapeutics, Inc. | Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas |
US20080076778A1 (en) | 2006-09-05 | 2008-03-27 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
US20110262485A1 (en) | 2008-08-04 | 2011-10-27 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
WO2010067262A1 (en) | 2008-12-09 | 2010-06-17 | Pfizer Inc. | Immunostimulatory oligonucleotides |
EP2405758B1 (en) | 2009-03-09 | 2016-04-27 | Molecular Express, Inc. | Methods and compositions for liposomal formulation of antigens and uses thereof |
US8414630B2 (en) | 2009-03-10 | 2013-04-09 | Marc Evan Richelsoph | Active bone screw |
BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
US8771933B2 (en) | 2009-10-06 | 2014-07-08 | Massachusetts Institute Of Technology | Continuous-flow deformability-based cell separation |
US20110293558A1 (en) | 2010-03-22 | 2011-12-01 | Massachusetts Institute Of Technology | Material properties of t cells and related methods and compositions |
BR112012027745A2 (pt) | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
JP5998370B2 (ja) | 2010-11-17 | 2016-09-28 | アデュロ バイオテック | Egfrviiiに対する免疫応答を誘発する方法および組成物 |
US9061048B2 (en) | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
US9880084B2 (en) | 2011-04-15 | 2018-01-30 | The University Of British Columbia | Apparatus for separation of particles |
WO2013086331A1 (en) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | High efficiency di-nucleotide cyclase |
CN104540945A (zh) | 2012-04-30 | 2015-04-22 | 格伦·N·巴伯 | 调节免疫应答 |
IN2014MN02492A (zh) | 2012-06-08 | 2015-07-17 | Aduro Biotech | |
US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
EP2931738B1 (en) * | 2012-12-13 | 2019-02-06 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
AU2013363087B2 (en) | 2012-12-19 | 2018-07-19 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
SG11201508165VA (en) | 2013-04-29 | 2015-11-27 | Sloan Kettering Inst Cancer | Compositions and methods for altering second messenger signaling |
WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
CN105188373B (zh) | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
-
2013
- 2013-06-07 IN IN2492MUN2014 patent/IN2014MN02492A/en unknown
- 2013-06-07 CN CN201380037917.2A patent/CN104507538B/zh not_active Expired - Fee Related
- 2013-06-07 US US13/912,960 patent/US9770467B2/en active Active
- 2013-06-07 SG SG10201610251PA patent/SG10201610251PA/en unknown
- 2013-06-07 KR KR1020157000522A patent/KR20150022996A/ko not_active Application Discontinuation
- 2013-06-07 AU AU2013271375A patent/AU2013271375B2/en not_active Ceased
- 2013-06-07 WO PCT/US2013/044744 patent/WO2013185052A1/en active Application Filing
- 2013-06-07 NZ NZ702392A patent/NZ702392A/en not_active IP Right Cessation
- 2013-06-07 SG SG11201407875UA patent/SG11201407875UA/en unknown
- 2013-06-07 JP JP2015516245A patent/JP6257607B2/ja not_active Expired - Fee Related
- 2013-06-07 EP EP13799826.6A patent/EP2858722B8/en not_active Not-in-force
- 2013-06-07 CA CA2876150A patent/CA2876150A1/en not_active Abandoned
-
2015
- 2015-05-21 HK HK15104847.0A patent/HK1204302A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2876150A1 (en) | 2013-12-12 |
KR20150022996A (ko) | 2015-03-04 |
AU2013271375B2 (en) | 2018-03-22 |
WO2013185052A1 (en) | 2013-12-12 |
EP2858722B8 (en) | 2018-02-21 |
HK1204302A1 (zh) | 2015-11-13 |
AU2013271375A1 (en) | 2014-12-18 |
US9770467B2 (en) | 2017-09-26 |
JP6257607B2 (ja) | 2018-01-10 |
EP2858722A4 (en) | 2015-12-23 |
US20150010613A1 (en) | 2015-01-08 |
EP2858722A1 (en) | 2015-04-15 |
IN2014MN02492A (zh) | 2015-07-17 |
CN104507538B (zh) | 2018-04-06 |
SG10201610251PA (en) | 2017-01-27 |
JP2015518901A (ja) | 2015-07-06 |
CN104507538A (zh) | 2015-04-08 |
NZ702392A (en) | 2017-03-31 |
EP2858722B1 (en) | 2017-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407875UA (en) | Compostions and methods for cancer immunotherapy | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201407340YA (en) | Treatment of myelosuppression | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201408652SA (en) | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201408228QA (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
SG11201901347UA (en) | Compositions and methods for cancer immunotherapy |